Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31133339 | 0.77 | NOS1 (0.42) | TRPA1ALDH1A1NOS1DYRK1ATDP1 | |
| SCHEMBL26632171 | 0.76 | NOS1 (0.41) | TRPA1ALDH1A1NOS1DYRK1A | |
| SCHEMBL24753063 | 0.75 | TRPA1 (0.49) | TRPA1SMN1; SMN2ALDH1A1NOS1DYRK1A | |
| SCHEMBL30726288 | 0.74 | KHK (0.44) | KHKTRPA1SMN1; SMN2ALDH1A1NOS1 | |
| SCHEMBL27039655 | 0.74 | KHK (0.44) | KHKTRPA1SMN1; SMN2ALDH1A1NOS1 | |
| SCHEMBL31162362 | 0.74 | IMPDH2 (0.43) | KHKSMN1; SMN2ALDH1A1DYRK1ANPSR1 | |
| SCHEMBL11574647 | 0.73 | TRPA1 (0.54) | TRPA1ALDH1A1NOS1DYRK1ACYP1A2 | |
| SCHEMBL1981821 | 0.71 | TRPA1 (0.48) | TRPA1ALDH1A1NOS1DYRK1ACYP1A2 | |
| SCHEMBL566209 | 0.71 | KHK (0.57) | KHKSMN1; SMN2ALDH1A1NPSR1CYP1A2 | |
| SCHEMBL29907178 | 0.70 | AXL (0.50) | TRPA1SMN1; SMN2ALDH1A1NOS1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GPR119 | KHK 3253/4885TRPA1 757/4885SMN1; SMN2 2476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.